<DOC>
	<DOCNO>NCT00114192</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , docetaxel , work different way stop growth tumor cell , either kill cell stop dividing . Thalidomide may stop growth non-small cell lung cancer block blood flow tumor . Thalidomide may also help docetaxel work well make tumor cell sensitive drug . Giving docetaxel together thalidomide may kill tumor cell . PURPOSE : This phase II trial study well give docetaxel together thalidomide work second-line therapy treat patient stage III stage IV non-small cell lung cancer .</brief_summary>
	<brief_title>Docetaxel Thalidomide Second-Line Therapy Treating Patients With Stage III Stage IV Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine complete partial response rate patient stage III IV non-small cell lung cancer treat docetaxel thalidomide second-line therapy . Secondary - Determine toxicity regimen patient . - Determine response duration survival patient treat regimen . - Determine quality life patient treat regimen . OUTLINE : This open-label study . Patients receive docetaxel IV 30-60 minute day 1 , 8 , 15 . Patients also receive oral thalidomide daily day -7 28 course 1 day 1-28 subsequent course . Treatment repeat every 28 day 6 course absence disease progression unacceptable toxicity . Patients stable respond disease 6 course treatment may continue study treatment discretion investigator . Patients discontinue docetaxel due toxicity may continue treatment thalidomide discretion investigator . Quality life assess baseline , treatment course , completion study treatment , every 3 month thereafter . After completion study treatment , patient follow every 3 month survival . PROJECTED ACCRUAL : A total 37 patient accrue study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm nonsmall cell lung cancer , meet 1 follow stage criterion : Stage IIIB ( pleural effusion ) Stage IIIA IIIB Previously treat eligible surgery definitive thoracic radiotherapy Stage IV Measurable evaluable disease Documented disease progression standard firstline chemotherapy may include taxane No untreated brain metastasis Patients previously treat brain metastasis eligible provide recovered prior treatment PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 02 Life expectancy Not specify Hematopoietic Absolute neutrophil count &gt; 1,500/mm^3 Hemoglobin ≥ 8.0 g/dL Platelet count &gt; 100,000/mm^3 Hepatic Bilirubin normal SGOT and/or SGPT ≤ 2.5 time upper limit normal ( ULN ) AND alkaline phosphatase normal OR SGOT and/or SGPT normal AND alkaline phosphatase ≤ 4 time ULN AND ascites Albumin &gt; 3.0 g/dL Renal Creatinine &lt; 1.5 mg/dL Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective doublemethod contraception 4 week , , ≥ 4 week completion study treatment No HIV positivity No peripheral neuropathy &gt; grade 1 No malignancy within past 5 year except inactive nonmelanoma skin cancer carcinoma situ cervix breast No active infection No history severe hypersensitivity reaction docetaxel drug formulate polysorbate 80 PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy See Disease Characteristics No 1 prior systemic chemotherapy regimen locally advance metastatic disease Prior neoadjuvant adjuvant systemic chemotherapy allow At least 4 week since prior chemotherapy recover Endocrine therapy Not specify Radiotherapy Recovered prior radiotherapy Surgery Not specify Other No concurrent investigational agent No concurrent anticancer therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
</DOC>